Oxford Biomedica PLC

Director's Dealing • Oct 14, 2022

National Storage Mechanism | Additional information

RNS Number : 9897C

Oxford Biomedica PLC

14 October 2022

PDMR Dealings

Oxford, UK - 14 October 2022: Oxford Biomedica plc ("Oxford Biomedica" or "the Company") (LSE:OXB), a leading gene and cell therapy group, was informed today, that Dr. James Miskin, Chief Technical Officer, exercised 19,540 LTIP (2017), 7,357 LTIP (2018) and 14,192 (2019) options at nil cost on 13 October 2022. All of the resulting 41,089 ordinary shares were sold at 320p per share on 13 October 2022. Following this transaction Dr. James Miskin holds options over 140,268 ordinary shares.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of ordinary shares exercised and then sold.

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")

a)

Name

James Miskin

2.

Reason for the notification

a)

Position/status

Chief Technical Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Options over ordinary shares of 50 pence each

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Exercise of options

c)

Currency

GBP - British pound

d)

Price(s) and volumes(s)

Price(s)	Volume(s)
Nil	41,089

e)

Aggregated information

-    Aggregate volume

-    Aggregate price

-    Aggregated total

41,089

Nil

Nil

f)

Date of the transaction

2022-10-13

g)

Place of the transaction

Outside a trading venue

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")

a)

Name

James Miskin

2.

Reason for the notification

a)

Position/status

Chief Technical Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary shares of 50 pence each

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Sale of ordinary shares

c)

Currency

GBP - British pound

d)

Price(s) and volumes(s)

Price(s)	Volume(s)
£3.20	41,089

e)

Aggregated information

-    Aggregate volume

-    Aggregated price

-    Aggregated total

41,089

£3.20

£131,484.80

f)

Date of the transaction

2022-10-13

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

-Ends-

For further information, please contact:
Oxford Biomedica plc: Natalie Walter, Company Secretary	Tel: +44 (0)1865 783 000

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, and is working on programmes from pre-clinical to commercial stage across a range of therapeutic areas with global partners.

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

Further information is available at www.oxb.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFFMFDLEESEES